Developer docs
API playgroundTry for free, no card

Search company profiles

Immix Biopharma

Full company profile

uuid00004l2

Namestring
Immix Biopharma
Legal namestring
Immix Biopharma, Inc.
Websiteurl
immixbio.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California and incorporated in Delaware, founded in 2022 by Ilya Rachman, MD PhD to develop cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company's lead candidate NXC-201 (formerly HBI0101) is a sterically-optimized, BCMA-targeted autologous CAR-T cell therapy produced through the proprietary N-GENIUS platform with EXPAND technology, into which global IP rights were licensed from Hadassah Israel. NXC-201 incorporates three proprietary modifications — Optimized CD3ζγ signaling, Enhanced CD8 Hinge acting as a "digital filter," and COBRA binder technology — designed to deliver precise intracellular signaling while reducing non-specific activation and cytokine release.

In May 2026 the company reported a 95% complete response rate (19 of 20 patients) in its U.S. NEXICART-2 Phase 1b/2 registrational trial, with 0% neurotoxicity across all treated patients and a median CRS duration of 1 day (4-8x shorter than competing BCMA CAR-Ts). The company holds four stacked regulatory designations for NXC-201 — FDA Breakthrough Therapy Designation (January 2026), FDA RMAT, FDA Orphan Drug Designation, and EU EMA Orphan Drug Designation — and is the only granted FDA Breakthrough Designation for an active development-stage therapy in relapsed/refractory AL amyloidosis. NEXICART-2 enrollment of 40 patients was completed March 30, 2026, with topline Phase 2 results expected Q3 2026, followed by BLA submission and a planned U.S. commercial launch in 2028.

The company is pre-revenue and funds development through public equity offerings, having raised approximately $265 million in gross proceeds across February 2024 ($15M), December 2025 ($100M upsized), and May 2026 ($150M) underwritten offerings, with an additional $100M ATM facility, providing an operational runway into mid-2028. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy administered through specialty hematology/oncology and academic medical centers, priced analogously to approved CAR-Ts (Breyanzi, Carvykti, Abecma). Commercial readiness is being built through the additions of Chief Medical Officer Richard Graydon (former Merck/J&J, BLA experience on KEYTRUDA, DARZALEX, CARVYKTI, IMBRUVICA) and Chief Commercial Officer Michael Grabow (former Chimerix, Spectrum, Amgen, 10+ drug launches). The AL amyloidosis market alone represents $1.4-2.8B in annual sales potential, with a broader $10B+ TAM across plasma cell-driven immune-mediated diseases in neurology, rheumatology, hematology, and vascular indications.

Short descriptiontext

Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy produced via its proprietary N-GENIUS platform, targeting relapsed/refractory AL amyloidosis patients — a rare disease with no FDA-approved treatments — and other plasma cell-driven immune-mediated diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, biopharmaceutical drug development, BCMA-targeted therapy, amyloidosis treatment, cell therapy platform
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
CAR-T Cell Therapy
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Future Biopharmaceutical Product Sales (Pre-Revenue)
TypeOne Time License
Description

Immix Biopharma is a clinical-stage biopharmaceutical company that is not yet generating product revenue. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy for relapsed/refractory AL Amyloidosis (and later expanded indications). As a one-time cell therapy, the model is closer to a one-time treatment per patient (analogous to other approved CAR-Ts such as Breyanzi, Carvykti, Abecma).

immixbio.com
2Capital Markets Financing (Equity Offerings)
TypeSubscription Recurring
Description

To date, the company has funded development through equity financings including a $15M public offering in February 2024, an upsized $100M underwritten offering in December 2025 (net proceeds ~$93.7M), and a $150M underwritten offering in May 2026 (net proceeds ~$140.65M). Also amended an at-the-market offering agreement for up to $100M with Citizens JMP Securities. These are not product revenue but are the company's primary cash inflows pre-commercialization.

immixbio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1No commercial product pricing available; pre-commercial clinical-stage biotech
ModelOther
Notes

Immix Biopharma is clinical-stage with no approved product; NXC-201 is not yet commercially available so no drug pricing is publicly disclosed. Stock offering pricing is referenced (e.g., $5.10 per share in Dec 2025 offering; $8.94 per share in May 2026 offering) but these are equity financings, not product pricing.

immixbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NXC-201
Description

Lead product candidate: a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for relapsed/refractory AL Amyloidosis and immune-mediated diseases.

immixbio.com
+2 more records
Core offering1 text field

Immix Biopharma develops NXC-201, a BCMA-targeted, sterically-optimized autologous CAR-T cell therapy, for the treatment of relapsed/refractory AL amyloidosis and other plasma cell-driven immune-mediated diseases. The company leverages its proprietary N-GENIUS cell therapy platform with EXPAND technology, incorporating three modifications (Optimized CD3ζγ signaling, Enhanced CD8 Hinge 'digital filter', and COBRA binder) to deliver 'digital' signaling precision while minimizing toxicity. Development is conducted through the ex-U.S. NEXICART-1 study and U.S. Phase 1b/2 NEXICART-2 registrational trial, with FDA Breakthrough Therapy, RMAT, and Orphan Drug designations in place.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 95% complete response rate (19 of 20 patients) in NEXICART-2 interim update for relapsed/refractory AL Amyloidosis, with all CRs reached within 1 year of follow-up and no relapses observed to date
+5 more records
Product overview1 text field

Immix Biopharma offers a platform-plus-candidate architecture rather than a single unified product: the proprietary N-GENIUS Platform with EXPAND technology is the discovery and manufacturing engine used to generate sterically-optimized CAR-T cell therapies, and NXC-201 is the lead BCMA-targeted CAR-T candidate produced from that platform. The clinical development of NXC-201 is conducted through two named programs — the ex-U.S. NEXICART-1 study and the U.S. Phase 1b/2 NEXICART-2 trial — which together support the lead indication of relapsed/refractory AL amyloidosis and have underpinned FDA Breakthrough Therapy, RMAT, and Orphan Drug designations as well as EU EMA Orphan Drug Designation.

Product and service1 record
1NXC-201
CategoryCell Therapy / CAR-T Product Candidate
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagship (Lead Site For U.S. Nexicart-2 Trial; Lead Investigator Heather Landau, Md)TypeStrategic or Co-development Partner
Description

Memorial Sloan Kettering Cancer Center is the lead site for the U.S. NEXICART-2 registrational Phase 2 clinical trial of NXC-201 for relapsed/refractory AL Amyloidosis. Heather Landau, MD, Director of the Amyloidosis Program at MSKCC, serves as lead investigator and Scientific Advisor to Immix Biopharma. She has authored more than 100 peer-reviewed publications and presented NEXICART-2 data at ASH 2025, ASCO 2025, and ASTCT 2026.

2Hadassah Israel (Hadassah Medical Center)
Strategic tierFlagship (Origin Of Nxc-201 / Hbi0101 Ip)TypeStrategic or Co-development Partner
Description

Hadassah Israel is the originator of the NXC-201 (formerly HBI0101) academic BCMA-CAR-T program. In 2022, Immix Biopharma licensed-in global rights to the intellectual property from Hadassah Israel following a systematic search to identify breakthrough cell therapies. The Hadassah team (Eyal Lebel, Nathalie Asherie, Cyrille Cohen, Polina Stepensky, Moshe Gatt) has been a continuous clinical research partner, with multiple publications in Journal of Clinical Oncology, Haematologica, and Clinical Cancer Research.

immixbio.com
Strategic tierMajor (Nexicart-2 Trial Site; Kol Engagement)TypeStrategic or Co-development Partner
Description

Cleveland Clinic is one of the NEXICART-2 clinical trial sites. Shahzad Raza, MD of Cleveland Clinic serves as a co-investigator and KOL, participating in KOL events to discuss NEXICART-2 Phase 2 results. Logo displayed on company 'Industry Leading Partners' page.

Strategic tierMajor (Nexicart-2 Trial Site; Kol Engagement)TypeStrategic or Co-development Partner
Description

Stanford Medicine is one of the NEXICART-2 clinical trial sites. Michaela Liedtke, MD, Stanford Amyloid Center Co-Director, serves as a KOL and Scientific Advisor. Logo displayed on company 'Industry Leading Partners' page.

5Harvard (Harvard Medical School / Massachusetts General Hospital)
Strategic tierMajor (Training/Clinical Research; Trial Site)TypeStrategic or Co-development Partner
Description

Harvard's Massachusetts General Hospital is referenced as the training site for Chief Medical Officer Richard Graydon, MD PhD. Harvard logo is displayed on the company 'Industry Leading Partners' page as an institutional partner.

immixbio.com
Strategic tierMajor (Nexicart-2 Trial Site)TypeStrategic or Co-development Partner
Description

UC San Diego is one of the NEXICART-2 clinical trial sites for the NXC-201 CAR-T cell therapy. Logo displayed on the company 'Industry Leading Partners' page.

7Sheppard, Mullin, Richter & Hampton LLP
Strategic tierCore (Legal Counsel)TypeImplementation/ SI/ Consulting Partner
Description

Sheppard, Mullin, Richter & Hampton LLP (30 Rockefeller Plaza, New York, NY 10112) serves as Immix Biopharma's legal counsel, per the Investor FAQ on the company website.

immixbio.com
Strategic tierCore (Auditor)TypeImplementation/ SI/ Consulting Partner
Description

Crow LLP serves as Immix Biopharma's auditor, per the Investor FAQ on the company website.

9Philadelphia Stock Transfer (PST)
Strategic tierCore (Transfer Agent)TypeImplementation/ SI/ Consulting Partner
Description

Philadelphia Stock Transfer, Inc. (2320 Haverford Road, Suite 230, Ardmore, PA 19003) serves as Immix Biopharma's transfer agent.

immixbio.com
Strategic tierAdvisory (Scientific Advisor)TypeStrategic or Co-development Partner
Description

Dr. Raymond Comenzo, Director of the Myeloma and Amyloid Program and Director of the Cell Therapy Laboratory at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine, serves as a Scientific Advisor to Immix Biopharma. Board certified in Internal Medicine and Hematology.

Strategic tierAdvisory (Scientific Advisor; Kol)TypeStrategic or Co-development Partner
Description

Dr. Vaishali Sanchorawala, Skinner Professor of Amyloidosis Research at Boston University Chobanian & Avedisian School of Medicine and Director of the Amyloidosis Center at Boston Medical Center, serves as a Scientific Advisor to Immix Biopharma and KOL speaker. Quoted on the company website.

Strategic tierAdvisory (Scientific Advisor)TypeStrategic or Co-development Partner
Description

Dr. Suzanne Lentzsch, Professor of Clinical Medicine and Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and New York Presbyterian Hospital, serves as a Scientific Advisor to Immix Biopharma. Co-founder of Caelum Biosciences (acquired by AstraZeneca).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Abecma, the first FDA-approved BCMA-directed CAR-T cell therapy for multiple myeloma, making it the most direct large-cap competitor in the BCMA CAR-T space. Both companies compete in BCMA-targeted autologous CAR-T development with overlapping manufacturing and clinical infrastructure.

TypeBroad incumbent
Description

J&J co-developed with Legend Biotech Carvykti, the leading FDA-approved BCMA CAR-T for multiple myeloma with industry-leading efficacy benchmarks. Directly comparable as a BCMA CAR-T competitor with established commercial CAR-T infrastructure that could expand into AL amyloidosis.

TypeDirect peer
Description

Allogene is a clinical-stage CAR-T company developing both allogeneic (off-the-shelf) and autologous CAR-T candidates, including BCMA-directed programs. Comparable as a public clinical-stage CAR-T peer pursuing similar hematology indications, with a complementary allogeneic approach.

TypeDirect peer
Description

CRISPR Therapeutics develops gene-edited cell therapies including allogeneic CAR-T candidates (e.g., CTX112 targeting CD19 and BCMA). Comparable as a clinical-stage public CAR-T peer with a similar regulatory pathway and platform-based cell therapy strategy.

TypeDirect peer
Description

Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based genome editing, with clinical programs in hematologic malignancies. Comparable as a clinical-stage CAR-T peer with similar modality, regulatory pathway, and platform expansion thesis.

TypeEmerging player
Description

Precision BioSciences develops in vivo gene-edited cell therapies including CAR-T candidates for hematologic malignancies. Comparable as an early-to-mid-stage cell therapy peer with adjacent modality and overlapping target indications.

TypeBroad incumbent
Description

AstraZeneca's Alexion rare-disease franchise acquired Caelum Biosciences (co-founded by Immix SAB member Suzanne Lentzsch) and has been active in AL amyloidosis. Comparable as a large-cap incumbent with rare-hematology commercial reach that could be a partner or competitor in the AL amyloidosis space.

TypeEmerging player
Description

Prothena is a clinical-stage biotech developing therapies for amyloid-related diseases including AL amyloidosis. Directly comparable as a small-cap public biotech tackling the same orphan indication with a complementary protein-targeting approach.

TypeDirect peer
Description

2seventy bio co-developed Abecma with BMS and remains the dedicated cell therapy entity post-spin-off. Comparable as a focused, clinical-to-commercial stage CAR-T peer with deep BCMA CAR-T expertise and ongoing multiple myeloma development.

TypeEmerging player
Description

Adaptimmune develops engineered T-cell therapies including SPEAR T-cells for hematologic malignancies, recently gaining FDA approval for Tecelra. Comparable as a clinical-to-commercial stage cell therapy peer with similar regulatory trajectory and platform-based expansion thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immix Biopharma

CAR-T Cell Therapyimmixbio.com

Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy produced via its proprietary N-GENIUS platform, targeting relapsed/refractory AL amyloidosis patients — a rare disease with no FDA-approved treatments — and other plasma cell-driven immune-mediated diseases.

What Immix Biopharma does

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California and incorporated in Delaware, founded in 2022 by Ilya Rachman, MD PhD to develop cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company's lead candidate NXC-201 (formerly HBI0101) is a sterically-optimized, BCMA-targeted autologous CAR-T cell therapy produced through the proprietary N-GENIUS platform with EXPAND technology, into which global IP rights were licensed from Hadassah Israel. NXC-201 incorporates three proprietary modifications — Optimized CD3ζγ signaling, Enhanced CD8 Hinge acting as a "digital filter," and COBRA binder technology — designed to deliver precise intracellular signaling while reducing non-specific activation and cytokine release.

In May 2026 the company reported a 95% complete response rate (19 of 20 patients) in its U.S. NEXICART-2 Phase 1b/2 registrational trial, with 0% neurotoxicity across all treated patients and a median CRS duration of 1 day (4-8x shorter than competing BCMA CAR-Ts). The company holds four stacked regulatory designations for NXC-201 — FDA Breakthrough Therapy Designation (January 2026), FDA RMAT, FDA Orphan Drug Designation, and EU EMA Orphan Drug Designation — and is the only granted FDA Breakthrough Designation for an active development-stage therapy in relapsed/refractory AL amyloidosis. NEXICART-2 enrollment of 40 patients was completed March 30, 2026, with topline Phase 2 results expected Q3 2026, followed by BLA submission and a planned U.S. commercial launch in 2028.

The company is pre-revenue and funds development through public equity offerings, having raised approximately $265 million in gross proceeds across February 2024 ($15M), December 2025 ($100M upsized), and May 2026 ($150M) underwritten offerings, with an additional $100M ATM facility, providing an operational runway into mid-2028. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy administered through specialty hematology/oncology and academic medical centers, priced analogously to approved CAR-Ts (Breyanzi, Carvykti, Abecma). Commercial readiness is being built through the additions of Chief Medical Officer Richard Graydon (former Merck/J&J, BLA experience on KEYTRUDA, DARZALEX, CARVYKTI, IMBRUVICA) and Chief Commercial Officer Michael Grabow (former Chimerix, Spectrum, Amgen, 10+ drug launches). The AL amyloidosis market alone represents $1.4-2.8B in annual sales potential, with a broader $10B+ TAM across plasma cell-driven immune-mediated diseases in neurology, rheumatology, hematology, and vascular indications.

Immix Biopharma firmographics

Firmographics
Name
Immix Biopharma
Legal name
Immix Biopharma, Inc.
Website
https://immixbio.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy produced via its proprietary N-GENIUS platform, targeting relapsed/refractory AL amyloidosis patients — a rare disease with no FDA-approved treatments — and other plasma cell-driven immune-mediated diseases.
Ownership category
akta.pro rank

Immix Biopharma industry classification

Industry
Product category
CAR-T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CAR-T cell therapy
  • Biopharmaceutical drug development
  • BCMA-targeted therapy
  • Amyloidosis treatment
  • Cell therapy platform

Where Immix Biopharma is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Immix Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Future Biopharmaceutical Product Sales (Pre-Revenue): Immix Biopharma is a clinical-stage biopharmaceutical company that is not yet generating product revenue. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy for relapsed/refractory AL Amyloidosis (and later expanded indications). As a one-time cell therapy, the model is closer to a one-time treatment per patient (analogous to other approved CAR-Ts such as Breyanzi, Carvykti, Abecma).
  2. Capital Markets Financing (Equity Offerings): To date, the company has funded development through equity financings including a $15M public offering in February 2024, an upsized $100M underwritten offering in December 2025 (net proceeds ~$93.7M), and a $150M underwritten offering in May 2026 (net proceeds ~$140.65M). Also amended an at-the-market offering agreement for up to $100M with Citizens JMP Securities. These are not product revenue but are the company's primary cash inflows pre-commercialization.

Pricing tiers

ModelBillingPrice
Other—No commercial product pricing available; pre-commercial clinical-stage biotech

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Immix Biopharma product offering

Product offering

Core offering

Immix Biopharma develops NXC-201, a BCMA-targeted, sterically-optimized autologous CAR-T cell therapy, for the treatment of relapsed/refractory AL amyloidosis and other plasma cell-driven immune-mediated diseases. The company leverages its proprietary N-GENIUS cell therapy platform with EXPAND technology, incorporating three modifications (Optimized CD3ζγ signaling, Enhanced CD8 Hinge 'digital filter', and COBRA binder) to deliver 'digital' signaling precision while minimizing toxicity. Development is conducted through the ex-U.S. NEXICART-1 study and U.S. Phase 1b/2 NEXICART-2 registrational trial, with FDA Breakthrough Therapy, RMAT, and Orphan Drug designations in place.

Product overview

Immix Biopharma offers a platform-plus-candidate architecture rather than a single unified product: the proprietary N-GENIUS Platform with EXPAND technology is the discovery and manufacturing engine used to generate sterically-optimized CAR-T cell therapies, and NXC-201 is the lead BCMA-targeted CAR-T candidate produced from that platform. The clinical development of NXC-201 is conducted through two named programs — the ex-U.S. NEXICART-1 study and the U.S. Phase 1b/2 NEXICART-2 trial — which together support the lead indication of relapsed/refractory AL amyloidosis and have underpinned FDA Breakthrough Therapy, RMAT, and Orphan Drug designations as well as EU EMA Orphan Drug Designation.

Differentiator

Problem solved

Functional benefit

Brands

  • NXC-201: Lead product candidate: a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for relapsed/refractory AL Amyloidosis and immune-mediated diseases.
  • N-GENIUS
  • Be Proactive in AL

Products and services

  • NXC-201

Quantifiable outcome

  • 95% complete response rate (19 of 20 patients) in NEXICART-2 interim update for relapsed/refractory AL Amyloidosis, with all CRs reached within 1 year of follow-up and no relapses observed to date
  • +5 more outcomes

Companies that use Immix Biopharma

Customer profile

Segments3 records

Ideal customer profiles2 records

Immix Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Immix Biopharma partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship (lead site for u.s. nexicart-2 trial; lead investigator heather landau, md), flagship (origin of nxc-201 / hbi0101 ip), major (nexicart-2 trial site; kol engagement), major (training/clinical research; trial site), major (nexicart-2 trial site), core (legal counsel), core (auditor), core (transfer agent), advisory (scientific advisor) and advisory (scientific advisor; kol).

  • Memorial Sloan Kettering Cancer Center (MSKCC)flagship (lead site for u.s. nexicart-2 trial; lead investigator heather landau, md)Strategic or Co-development PartnerMemorial Sloan Kettering Cancer Center is the lead site for the U.S. NEXICART-2 registrational Phase 2 clinical trial of NXC-201 for relapsed/refractory AL Amyloidosis. Heather Landau, MD, Director of the Amyloidosis Program at MSKCC, serves as lead investigator and Scientific Advisor to Immix Biopharma. She has authored more than 100 peer-reviewed publications and presented NEXICART-2 data at ASH 2025, ASCO 2025, and ASTCT 2026.
  • Hadassah Israel (Hadassah Medical Center)flagship (origin of nxc-201 / hbi0101 ip)Strategic or Co-development PartnerHadassah Israel is the originator of the NXC-201 (formerly HBI0101) academic BCMA-CAR-T program. In 2022, Immix Biopharma licensed-in global rights to the intellectual property from Hadassah Israel following a systematic search to identify breakthrough cell therapies. The Hadassah team (Eyal Lebel, Nathalie Asherie, Cyrille Cohen, Polina Stepensky, Moshe Gatt) has been a continuous clinical research partner, with multiple publications in Journal of Clinical Oncology, Haematologica, and Clinical Cancer Research.
  • Cleveland Clinicmajor (nexicart-2 trial site; kol engagement)Strategic or Co-development PartnerCleveland Clinic is one of the NEXICART-2 clinical trial sites. Shahzad Raza, MD of Cleveland Clinic serves as a co-investigator and KOL, participating in KOL events to discuss NEXICART-2 Phase 2 results. Logo displayed on company 'Industry Leading Partners' page.
  • Stanford Medicine (Stanford University)major (nexicart-2 trial site; kol engagement)Strategic or Co-development PartnerStanford Medicine is one of the NEXICART-2 clinical trial sites. Michaela Liedtke, MD, Stanford Amyloid Center Co-Director, serves as a KOL and Scientific Advisor. Logo displayed on company 'Industry Leading Partners' page.
  • Harvard (Harvard Medical School / Massachusetts General Hospital)major (training/clinical research; trial site)Strategic or Co-development PartnerHarvard's Massachusetts General Hospital is referenced as the training site for Chief Medical Officer Richard Graydon, MD PhD. Harvard logo is displayed on the company 'Industry Leading Partners' page as an institutional partner.
  • UC San Diegomajor (nexicart-2 trial site)Strategic or Co-development PartnerUC San Diego is one of the NEXICART-2 clinical trial sites for the NXC-201 CAR-T cell therapy. Logo displayed on the company 'Industry Leading Partners' page.
  • Sheppard, Mullin, Richter & Hampton LLPcore (legal counsel)Implementation/ SI/ Consulting PartnerSheppard, Mullin, Richter & Hampton LLP (30 Rockefeller Plaza, New York, NY 10112) serves as Immix Biopharma's legal counsel, per the Investor FAQ on the company website.
  • Crow LLPcore (auditor)Implementation/ SI/ Consulting PartnerCrow LLP serves as Immix Biopharma's auditor, per the Investor FAQ on the company website.
  • Philadelphia Stock Transfer (PST)core (transfer agent)Implementation/ SI/ Consulting PartnerPhiladelphia Stock Transfer, Inc. (2320 Haverford Road, Suite 230, Ardmore, PA 19003) serves as Immix Biopharma's transfer agent.
  • Tufts University School of Medicine (Dr. Raymond Comenzo)advisory (scientific advisor)Strategic or Co-development PartnerDr. Raymond Comenzo, Director of the Myeloma and Amyloid Program and Director of the Cell Therapy Laboratory at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine, serves as a Scientific Advisor to Immix Biopharma. Board certified in Internal Medicine and Hematology.
  • Boston University (Dr. Vaishali Sanchorawala)advisory (scientific advisor; kol)Strategic or Co-development PartnerDr. Vaishali Sanchorawala, Skinner Professor of Amyloidosis Research at Boston University Chobanian & Avedisian School of Medicine and Director of the Amyloidosis Center at Boston Medical Center, serves as a Scientific Advisor to Immix Biopharma and KOL speaker. Quoted on the company website.
  • Columbia University (Dr. Suzanne Lentzsch)advisory (scientific advisor)Strategic or Co-development PartnerDr. Suzanne Lentzsch, Professor of Clinical Medicine and Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and New York Presbyterian Hospital, serves as a Scientific Advisor to Immix Biopharma. Co-founder of Caelum Biosciences (acquired by AstraZeneca).

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Immix Biopharma competitors and assessment

Company assessment

Broad incumbents

  • Bristol Myers Squibb: BMS markets Abecma, the first FDA-approved BCMA-directed CAR-T cell therapy for multiple myeloma, making it the most direct large-cap competitor in the BCMA CAR-T space. Both companies compete in BCMA-targeted autologous CAR-T development with overlapping manufacturing and clinical infrastructure.
  • Johnson & Johnson (Janssen) / Legend Biotech: J&J co-developed with Legend Biotech Carvykti, the leading FDA-approved BCMA CAR-T for multiple myeloma with industry-leading efficacy benchmarks. Directly comparable as a BCMA CAR-T competitor with established commercial CAR-T infrastructure that could expand into AL amyloidosis.
  • AstraZeneca (Alexion): AstraZeneca's Alexion rare-disease franchise acquired Caelum Biosciences (co-founded by Immix SAB member Suzanne Lentzsch) and has been active in AL amyloidosis. Comparable as a large-cap incumbent with rare-hematology commercial reach that could be a partner or competitor in the AL amyloidosis space.

Direct peers

  • Allogene Therapeutics: Allogene is a clinical-stage CAR-T company developing both allogeneic (off-the-shelf) and autologous CAR-T candidates, including BCMA-directed programs. Comparable as a public clinical-stage CAR-T peer pursuing similar hematology indications, with a complementary allogeneic approach.
  • CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited cell therapies including allogeneic CAR-T candidates (e.g., CTX112 targeting CD19 and BCMA). Comparable as a clinical-stage public CAR-T peer with a similar regulatory pathway and platform-based cell therapy strategy.
  • Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based genome editing, with clinical programs in hematologic malignancies. Comparable as a clinical-stage CAR-T peer with similar modality, regulatory pathway, and platform expansion thesis.
  • 2seventy bio: 2seventy bio co-developed Abecma with BMS and remains the dedicated cell therapy entity post-spin-off. Comparable as a focused, clinical-to-commercial stage CAR-T peer with deep BCMA CAR-T expertise and ongoing multiple myeloma development.

Emerging players

  • Precision BioSciences: Precision BioSciences develops in vivo gene-edited cell therapies including CAR-T candidates for hematologic malignancies. Comparable as an early-to-mid-stage cell therapy peer with adjacent modality and overlapping target indications.
  • Prothena Corporation: Prothena is a clinical-stage biotech developing therapies for amyloid-related diseases including AL amyloidosis. Directly comparable as a small-cap public biotech tackling the same orphan indication with a complementary protein-targeting approach.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies including SPEAR T-cells for hematologic malignancies, recently gaining FDA approval for Tecelra. Comparable as a clinical-to-commercial stage cell therapy peer with similar regulatory trajectory and platform-based expansion thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Immix Biopharma social profiles

Digital presence

Immix Biopharma compliance and trust

Trust signal

Compliance4 records

Immix Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immix Biopharma leadership team

Management profile

Number of profiles

Profiles8 records

Immix Biopharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immix Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immix Biopharma

What does Immix Biopharma do?

Immix Biopharma develops NXC-201, a BCMA-targeted, sterically-optimized autologous CAR-T cell therapy, for the treatment of relapsed/refractory AL amyloidosis and other plasma cell-driven immune-mediated diseases. The company leverages its proprietary N-GENIUS cell therapy platform with EXPAND technology, incorporating three modifications (Optimized CD3ζγ signaling, Enhanced CD8 Hinge 'digital filter', and COBRA binder) to deliver 'digital' signaling precision while minimizing toxicity. Development is conducted through the ex-U.S. NEXICART-1 study and U.S. Phase 1b/2 NEXICART-2 registrational trial, with FDA Breakthrough Therapy, RMAT, and Orphan Drug designations in place.

Is Immix Biopharma a public or private company?

Immix Biopharma is a public company. It is classified as public and is currently operating.

When was Immix Biopharma founded?

Immix Biopharma was founded in 2022. It employs 11 to 50 people.

Where is Immix Biopharma based?

Immix Biopharma is headquartered in Los Angeles, United States, in the North America region.

How does Immix Biopharma make money?

Two revenue lines are on record. Future Biopharmaceutical Product Sales (Pre-Revenue) is the primary driver. The others are capital Markets Financing (Equity Offerings).

Who are Immix Biopharma's main competitors?

Broad incumbents on record are Bristol Myers Squibb, Johnson & Johnson (Janssen) / Legend Biotech and AstraZeneca (Alexion). Direct peers are Allogene Therapeutics, CRISPR Therapeutics, Caribou Biosciences and 2seventy bio. Emerging players are Precision BioSciences, Prothena Corporation and Adaptimmune Therapeutics.

Does Immix Biopharma have an API?

No public API is recorded for Immix Biopharma.

What industry is Immix Biopharma in?

Immix Biopharma's product category is CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldAberdeen Group plc Buys New Shares in Immix Biopharma, Inc. $IMMXAberdeen Group plc acquired a new stake in Immix Biopharma, buying 818,674 shares worth about $8.5 million in Q3. The firm now holds 1.14% of the company, and institutional investors own 11.26% of the stock. Analysts have an average rating of Moderate Buy with a target price of $24.14.TradingViewMorgan Stanley maintains Immix Biopharma at Overweight, raises price target to $21 from $20Morgan Stanley maintained Immix Biopharma at Overweight and raised its price target to $21 from $20, a 5% increase. The target implies 191.7% upside from the Nov 17 close of $7.20.TradingViewMizuho maintains Immix Biopharma at Outperform, lowers price target to $22 from $23Mizuho maintained Immix Biopharma at Outperform and lowered its price target to $22 from $23, a 4.3% decrease. The target implies an upside of 205.6% from the Nov 17 close of $7.20.The future of tradingImmix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026Immix Biopharma will present interim NXC-201 trial results from 45 patients at the American Society of Hematology meeting on December 14, 2026. The NEXICART-2 study evaluates safety and efficacy in the first U.S. CAR-T trial for relapsed or refractory AL amyloidosis.Stock TitanImmix Biopharma to present 45-patient NXC-201 data at ASHImmix Biopharma will present interim NXC-201 trial data from the NEXICART-2 study at the ASH 2026 meeting on December 14, 2026. The oral presentation covers 45-patient safety and efficacy results for the BCMA-targeted CAR-T therapy in relapsed/refractory AL amyloidosis.MarketBeatImmix Biopharma (IMMX) Projected to Release Earnings on FridayImmix Biopharma is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting a loss of $0.18 per share. The company previously missed estimates with a $0.18 loss, and analysts have a consensus price target of $23.86. A conference call is scheduled for November 10th.American Banking and Market NewsImmix Biopharma (IMMX) Set to Release Quarterly Earnings on FridayImmix Biopharma will release its Q3 2026 earnings on Friday, November 6th, with analysts expecting a loss of $0.18 per share. The company previously missed estimates with a $0.18 loss, and analysts forecast a $0.76 loss for the current fiscal year. The stock opened at $7.98, with a consensus rating of Moderate Buy and an average target price of $23.86.American Banking and Market NewsImmix Biopharma, Inc. (NASDAQ:IMMX) Stock Rated “Moderate Buy” by Wall Street AnalystsImmix Biopharma received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $24.29. The stock opened at $8.15, and institutional investors hold 11.26% of the company. The company reported a quarterly loss of $0.18 per share, missing the consensus estimate.MarketBeatImmix Biopharma, Inc. (IMMX) - What Are Researchers Saying About This Stock?Immix Biopharma received a Moderate Buy consensus from nine analysts, with an average 1-year price target of $24.29. Citigroup reiterated a market outperform rating, while Weiss Ratings reaffirmed a sell. The stock opened at $8.22, and analysts predict a -0.74 EPS for the current year.